Lost money in y-mabs therapeutics, inc.?

Oakland, calif.--( business wire )--y-mabs therapeutics, inc. shares plummeted over 59% on october 31, 2022, after an fda advisory committee voted against approving the company's neuroblastoma drug omburtamab on october 28, 2022, according to marketwatch. gibbs law group is investigating a potential y-mabs therapeutics (ymab) securities class action lawsuit on behalf of shareholders who lost money in y-mabs therapeutics, inc. (nasdaq: ymab).
YMAB Ratings Summary
YMAB Quant Ranking